Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Children's Cancers | Ependymoma
  • Age: Between 1 - 21 Years
  • Gender: Male or Female
Inclusion Criteria
Histologically confirmed intracranial ependymoma
Newly diagnosed disease
lassic ependymoma (WHO II) or anaplastic ependymoma (WHO III)
No diagnosis of spinal cord ependymoma, myxopapillary ependymoma, subependymoma, ependymoblastoma, or mixed glioma
Has undergone surgical resection of the primary tumor
More than 1 attempted resection allowed
No metastatic disease by MRI or cerebrospinal fluid (CSF) cytology
CSR cytology from a ventriculostomy or permanent VP shunt that reveals the presence of tumor cells is indicative of metastatic disease
No evidence of non-contiguous spread beyond the primary site as determined by pre- or post-operative MRI of brain, pre- or post-operative MRI of the spine, and post-operative CSF cytology obtained from the lumbar CSF space
Lumbar CSF examination may be waived if deemed to be medically contraindicated
ECOG performance status (PS) 0-2
Karnofsky PS for patients > 16 years of age
Lansky PS for patients ? 16 years of age
Not pregnant or nursing
Patients who agree to stop nursing while on this study are allowed
Negative pregnancy test
Fertile patients must use effective contraception
No prior treatment for ependymoma other than surgical intervention and corticosteroids


Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.